Verona Pharma

$5.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-1.21%) Today
-$0.20 (-3.51%) As of 8:25 AM EDT after-hours

Why Robinhood?

You can buy or sell Verona Pharma and other stocks, options, and ETFs commission-free!

About VRNA

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Read More The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom. The listed name for VRNA is Verona Pharma plc American Depositary Share.

Employees
25
Headquarters
London, Greater London
Founded
2005
Market Cap
295.36M
Price-Earnings Ratio
Dividend Yield
Average Volume
138.59K
High Today
$5.77
Low Today
$5.50
Open Price
$5.77
Volume
38.81K
52 Week High
$15.71
52 Week Low
$2.01

Collections

VRNA Earnings

-$1.09
-$0.73
-$0.36
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 6, Pre-Market

You May Also Like